

Ditto A, De Cecco L, Paolini B, **Alberti P**, Martinelli F, Leone Roberti Maggiore U, Bogani G, Chiodini P, Pignata S, **Tomassetti A**, Raspagliesi F, **Mezzanzanica D**, **Bagnoli M**. Validation of MiROvaR, a microRNA-based predictor of early relapse in early stage epithelial ovarian cancer as a new strategy to optimise patients' prognostic assessment. *Eur J Cancer*. 2022 Jan;161:55-63. doi: 10.1016/j.ejca.2021.11.003. Epub 2021 Dec 15. PMID: 34922264

Marceca G, Distefano R, Tomasello L, Lagana A, Russo F, Calore F, Romano G, **Bagnoli M**, Gasparini P, Ferro A, Acunzo M, Ma Q, Croce CM, and Nigita G. MiREDiBase, a manually curated database of validated and putative editing events in microRNAs" *Sci Data*. 2021 Aug 4;8(1):199. doi: 10.1038/s41597-021-00979-8. PMID: 34349127.

De Cecco L, **Bagnoli M**, Chiodini P, Pignata S, **Mezzanzanica D**. Prognostic Evidence of the miRNA-Based Ovarian Cancer Signature MiROvaR in Independent Datasets. *Cancers (Basel)*. 2021 Mar 27;13(7):1544. doi: 10.3390/cancers13071544. PMID: 33801595; PMCID: PMC8037414.

Rizzo A, Satta A, Garrone G, Cavalleri A, **Napoli A**, Raspagliesi F, Figini M, De Cecco L, Iorio E, **Tomassetti A**, **Mezzanzanica D**, **Bagnoli M**. Choline kinase alpha impairment overcomes TRAIL resistance in ovarian cancer cells. *J Exp Clin Cancer Res*. 2021 Jan 4;40(1):5. doi: 10.1186/s13046-020-01794-6. PMID: 33390181.

Bogani G, Apolone G, Ditto A, Scambia G, Panici PB, Angioli R, Pignata S, Greggi S, Scollo P, **Delia M**, Franchi M, Martinelli F, Signorelli M, Lopez S, Di Donato V, Valabrega G, Ferrandina G, Palaia I, Bergamini A, Bocciolone L, Savarese A, Ghezzi F, Casarin J, Pinelli C, Trojano V, Chiantera V, Giorda G, Sopracordevole F, Malzoni M, Salerno G, Sartori E, Testa A, Zannoni G, Zullo F, Vizza E, Trojano G, Chiantera A, Raspagliesi F. Impact of COVID-19 in gynecologic oncology: a Nationwide Italian Survey of the SIGO and MITO groups. *J Gynecol Oncol*. 2020 Nov;31(6):e92. doi: 10.3802/jgo.2020.31.e92. PMID: 33078597; PMCID: PMC7593217.

Fraguas-Sánchez AI, Fernández-Carballido A, Delie F, Cohen M, Martin-Sabroso C, **Mezzanzanica D**, Figini M, Satta A, Torres-Suárez AI. Enhancing ovarian cancer conventional chemotherapy through the combination with cannabidiol loaded microparticles. *Eur J Pharm Biopharm*. 2020 Sep 10.1016/j.ejpb.2020.07.008. Epub 2020 Jul 17. PMID: 32682943.

Califano D, Russo D, Scognamiglio G, Losito NS, Spina A, Bello AM, Capiluongo A, Galdiero F, De Cecio R, Bevilacqua S, Gargiulo P, Marchesi E, Canevari S, Perrone F, Daniele G, De Cecco L, **Mezzanzanica D**, Pignata S. Ovarian Cancer Translational Activity of the Multicenter Italian Trial in Ovarian Cancer (MITO) Group: Lessons Learned in 10 Years of Experience. *Cells*. 2020 Apr 7 doi: 10.3390/cells9040903. PMID: 32272732

Satta A, Grazia G, Caroli F, Frigerio B, Di Nicola M, Raspagliesi F, **Mezzanzanica D**, Zaffaroni N, Gianni AM, Anichini A, Figini M. A Bispecific Antibody to Link a TRAIL-Based Antitumor Approach to Immunotherapy. *Front Immunol*. 2019 Oct 25 PMCID: PMC6823250.

Dugo M, Devecchi A, De Cecco L, Cecchin E, **Mezzanzanica D**, Sensi M, **Bagnoli M**. Focal Recurrent Copy Number Alterations Characterize Disease Relapse in High Grade Serous Ovarian Cancer Patients with Good Clinical Prognosis: A Pilot Study. *Genes (Basel)*. 2019 Sep 5;10(9). pii: E678. doi: 10.3390/genes10090678. PubMed PMID: 31491988.

Antony F, Deantonio C, Cotella D, Soluri MF, Tarasiuk O, Raspagliesi F, Adorni F, Piazza S, Ciani Y, Santoro C, Macor P, **Mezzanzanica D**, Sblattero D. High-throughput assessment of

the antibody profile in ovarian cancer ascitic fluids. *Oncoimmunology*. 2019 Jun 4;8(9):e1614856. doi: 10.1080/2162402X.2019.1614856. PMID: 31428516; PMCID: PMC6685609.

Bagnoli M, Shi TY, Gourley C, Speiser P, Reuss A, Nijman HW, Creutzberg CL, Scholl S, Negrouk A, Brady MF, Hasegawa K, Oda K, McNeish IA, Kohn EC, Oza AM, MacKay H, Millan D, Bennett K, Scott C, **Mezzanzanica D**. Gynecological Cancers Translational, Research Implementation, and Harmonization: Gynecologic Cancer InterGroup Consensus and Still Open Questions. *Cells*. 2019 Feb 26;8(3). pii:E200. doi: 10.3390/cells8030200. PubMed PMID: 30813545; PubMed Central PMCID:PMC6468728.

Roggiani F, Riva C, Raspagliesi F, Porta G, Valli R, Taramelli R, Acquati F, **Mezzanzanica D**, **Tomassetti A**. A Cell-Autonomous Oncosuppressive Role of Human RNASET2 Affecting ECM-Mediated Oncogenic Signaling. *Cancers (Basel)*. 2019 Feb 22;11(2):255. doi: 10.3390/cancers11020255. PMID: 30813308; PMCID: PMC6406318.

Canese R, Palombelli G, Chirico M, Sestili P, **Bagnoli M**, Canevari S, **Mezzanzanica D**, Podo F, Iorio E. Integration of MRI and MRS approaches to monitor molecular imaging and metabolomic effects of trabectedin on a preclinical ovarian cancer model. *NMR Biomed*. 2019 Oct;32(10):e4016. doi: Canese R, Palombelli G, Chirico M, Sestili P, Bagnoli M, Canevari S, Mezzanzanica D, Podo F, Iorio E. Integration of MRI and MRS approaches to monitor molecular imaging and metabolomic effects of trabectedin on a preclinical ovarian cancer model. *NMR Biomed*. 2019 Oct;32(10):e4016. doi: 10.1002/nbm.4016. Epub 2018 Oct 30. PMID: 30375088.